Winton Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,085
| Closed | -$227K | – | 808 |
|
|
2025
Q1 | $227K | Buy |
+1,085
| New | +$211K | 0.01% | 610 |
|
|
2024
Q1 | – | Sell |
-19,542
| Closed | -$3.03M | – | 584 |
|
|
2023
Q4 | $3.03M | Sell |
19,542
-15,523
| -44% | -$2.26M | 0.22% | 70 |
|
|
2023
Q3 | $5.23M | Buy |
+35,065
| New | +$5.15M | 0.43% | 33 |
|
|
2023
Q2 | – | Sell |
-17,422
| Closed | -$2.78M | – | 748 |
|
|
2023
Q1 | $2.78M | Sell |
17,422
-1,485
| -8% | -$227K | 0.17% | 130 |
|
|
2022
Q4 | $3.06M | Buy |
+18,907
| New | +$2.9M | 0.2% | 107 |
|
|
2022
Q2 | – | Sell |
-8,149
| Closed | -$1.32M | – | 933 |
|
|
2022
Q1 | $1.32M | Buy |
+8,149
| New | +$1.18M | 0.07% | 377 |
|
|
2020
Q2 | – | Sell |
-25,968
| Closed | -$1.98M | – | 1428 |
|
|
2020
Q1 | $1.98M | Buy |
+25,968
| New | +$2.21M | 0.05% | 582 |
|
|
2019
Q4 | – | Sell |
-197,137
| Closed | -$14.9M | – | 1518 |
|
|
2019
Q3 | $14.9M | Buy |
197,137
+170,116
| +630% | +$11.7M | 0.18% | 161 |
|
|
2019
Q2 | $1.97M | Buy |
27,021
+23,831
| +747% | +$1.87M | 0.04% | 289 |
|
|
2019
Q1 | $257K | Sell |
3,190
-1,138
| -26% | -$93.1K | 0.01% | 858 |
|
|
2018
Q4 | $399K | Sell |
4,328
-807
| -16% | -$71K | 0.01% | 556 |
|
|
2018
Q3 | $486K | Sell |
5,135
-584
| -10% | -$55.4K | 0.01% | 638 |
|
|
2018
Q2 | $530K | Sell |
5,719
-55,066
| -91% | -$5.38M | 0.01% | 624 |
|
|
2018
Q1 | $5.75M | Buy |
60,785
+37,370
| +160% | +$4.11M | 0.16% | 198 |
|
|
2017
Q4 | $2.26M | Sell |
23,415
-201,574
| -90% | -$19M | 0.07% | 364 |
|
|
2017
Q3 | $20M | Buy |
224,989
+78,484
| +54% | +$5.97M | 0.64% | 30 |
|
|
2017
Q2 | $10.6M | Buy |
146,505
+47,980
| +49% | +$3.23M | 0.31% | 96 |
|
|
2017
Q1 | $6.42M | Sell |
98,525
-7,599
| -7% | -$478K | 0.17% | 164 |
|
|
2016
Q4 | $6.64M | Sell |
106,124
-195,431
| -65% | -$11.9M | 0.22% | 143 |
|
|
2016
Q3 | $19M | Buy |
301,555
+20,155
| +7% | +$1.3M | 0.33% | 117 |
|
|
2016
Q2 | $17.4M | Buy |
281,400
+118,411
| +73% | +$7.22M | 0.29% | 134 |
|
|
2016
Q1 | $9.31M | Buy |
+162,989
| New | +$9.08M | 0.1% | 231 |
|
|
2015
Q4 | – | Sell |
-35,886
| Closed | -$1.95M | – | 313 |
|
|
2015
Q3 | $1.95M | Sell |
35,886
-23,096
| -39% | -$1.5M | 0.02% | 354 |
|
|
2015
Q2 | $3.96M | Sell |
58,982
-262,939
| -82% | -$17.2M | 0.04% | 332 |
|
|
2015
Q1 | $18.8M | Buy |
321,921
+166,306
| +107% | +$10M | 0.15% | 226 |
|
|
2014
Q4 | $10.2M | Sell |
155,615
-323,075
| -67% | -$20.4M | 0.13% | 256 |
|
|
2014
Q3 | $27.6M | Sell |
478,690
-545,478
| -53% | -$30.3M | 0.2% | 208 |
|
|
2014
Q2 | $57.8M | Buy |
+1,024,168
| New | +$53.7M | 0.39% | 73 |
|
Other funds holding ABBV
Winton Group's ABBV Position: Q2 2025 in Review
Winton Group sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 1,085 shares — an estimated $227K sold.
Winton Group first reported a position in ABBV in Q2 2014 and held it in 28 quarters. The position peaked at $57.8M in Q2 2014. 3,782 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.
- Winton Group reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
- Winton Group sold 1,085 AbbVie shares in Q2 2025, an estimated $227K.
- Winton Group first reported a position in AbbVie in Q2 2014 and held it in 28 quarters.
- Winton Group's AbbVie position peaked at $57.8M in Q2 2014.
- 3,782 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.
Based on Winton Group's 13F filing for Q2 2025, filed 14 Aug 2025.